Business Wire

Patient Safety Movement Foundation Honors Ruth Ann Dorrill, Kimberly Cripe, Dr. Peter Lachman with Humanitarian Awards and Dr. Mike Durkin with Lifetime Achievement Award

Share

Capping an eventful two days at the 11th Annual World Patient Safety, Science & Technology Summit, the Patient Safety Movement Foundation (PSMF) presented its prestigious Humanitarian Awards to visionaries and change agents in patient safety. The honorees were Ruth Ann Dorrill, Assistant Inspector General, Office of Evaluation and Inspections, Office of Inspector General; Kimberly Chavalas Cripe, the President and Chief Executive Officer at Children’s Hospital of Orange County; and Dr. Peter Lachman, Lead, Faculty Quality Improvement, Royal College of Physicians of Ireland. A special Lifetime Achievement Award was given to Dr. Mike Durkin, Chair of the PSMF’s Governance Board.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240909880433/en/

2024 Humanitarian Award recipients (left column, from top to bottom): Ruth Ann Dorrill, Assistant Inspector General, Office of Evaluation and Inspections, Office of Inspector General, with Joe Kiani and Dr. Mike Durkin; Kimberly Chavalas Cripe, the President and Chief Executive Officer at Children’s Hospital of Orange County, with Joe Kiani; Dr. Peter Lachman, Lead, Faculty Quality Improvement, Royal College of Physicians of Ireland, with Joe Kiani and Dr. Mike Durkin. Main image (right): Joe Kiani presents Dr. Mike Durkin with Lifetime Achievement Award. (Photo: Business Wire)

Each year since 2013, the PSMF’s Humanitarian Award is presented to a select group of distinguished individuals who have left an indelible mark on healthcare and helped shape the future of patient safety. As visionary leaders in their respective fields, they have implemented innovative, evidence-based, and sustainable solutions that transform the landscape of healthcare safety. This award honors their outstanding achievements so that they may serve as beacons of hope and sources of inspiration in the pursuit of zero harm and creating a safer, more just healthcare system for all.

The PSMF Lifetime Achievement Award is the highest award the PSMF can bestow. This individual will have made significant contributions in the area of patient safety throughout their career, and their achievements will have helped propel the medical community toward zero preventable patient and healthcare worker harm.

“It’s an honor to work with such a dedicated group of individuals whose contributions toward advancing patient safety are saving lives,” said PSMF Founder Joe Kiani. “As everyone in this field knows, we can’t do it alone, and these individuals represent the mentors we need to eliminate preventable patient harm in our hospitals and create a safer healthcare system for all.”

Ruth Ann Dorrill works for the U.S. Department of Health and Human Services as the Assistant Inspector General in the Office of Evaluation and Inspections, Office of Inspector General (OIG). Dorrill has been with the OIG for 28 years, leading the OIG’s work in patient harm for 15 years. She has led national studies in evaluating hospital and nursing quality, safety, and emergency preparedness, and has directed management reviews of HHS programs, including the Centers for Medicare & Medicaid Services implementation of HealthCare.gov and management of the Indian Health Service. She has testified before the U.S. House of Representatives Energy and Commerce Committee regarding nursing home quality and in 2021 received the Council of the Inspectors General on Integrity and Efficiency Lifetime Achievement Award.

As the President and Chief Executive Officer of Children’s Hospital of Orange County (CHOC) since 1997, Kimberly Chavalas Cripe has made significant advances in improving patient care, outcomes, and experience, while cultivating a growing healthcare community rooted in a culture of safety, excellence, innovation, and collaboration. Under Cripe’s leadership, CHOC has become a forerunner of population health management with the singular goal of fulfilling CHOC’s mission to advance and protect the health and well-being of children. Among many other initiatives, Cripe spearheaded efforts at CHOC to establish a robust pediatric system of mental healthcare designed to be scalable and replicable by other health systems. Cripe also serves as president of the CHOC Foundation, which raises funds to support pediatric healthcare.

Dr. Peter Lachman serves as Lead, Faculty Quality Improvement, at the Royal College of Physicians of Ireland (RCPI) in Dublin, where he directs the Leadership and Quality program to develop clinical leaders in quality improvement. He was Chief Executive Officer of the International Society for Quality in Healthcare (ISQua) from 2016 to 2021 and was a Health Foundation Quality Improvement Fellow at the Institute for Healthcare Improvement in 2005–2006. Dr. Lachman was also the National Clinical Lead for SAFE, a Royal College of Paediatrics and Child Health program that aims to improve situation awareness in clinical teams across England and Ireland. In addition, his work for PSMF includes editing Handbook publications on patient safety, medical management, and quality improvement, and leading the Global Interprofessional Patient Safety Fellowship program.

Dr. Mike Durkin, who is the current Chair of the Patient Safety Movement Foundation’s Governance Board, was honored with a special Lifetime Achievement Award by PSMF Founder Joe Kiani. In addition to his work for PSMF, Dr. Durkin is the Senior Advisor on Patient Safety Policy and Leadership, Institute of Global Health Innovation, Imperial College London. He is recognized as one of the world’s foremost authorities on patient safety and holds numerous advisory positions, serving as Senior Advisor on Patient Safety Policy and Leadership for the NIHR Imperial College Patient Safety Translational Research Centre in the U.K., and Academic Director of the Global Patient Safety Collaborative, a partnership between the World Health Organization (WHO) and the U.K. government. Dr. Durkin previously held clinical, research, and teaching positions in cardiovascular anesthesia and critical care in the U.K. and the U.S. before embarking on a 25-year career in medical management and leadership, culminating in an appointment as National Health Service (NHS) Medical Director across the South of England. Durkin subsequently served as the NHS National Director of Patient Safety.

PATIENT SAFETY MOVEMENT FOUNDATION

In 2012, Joe Kiani founded the nonprofit Patient Safety Movement Foundation to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices that address top challenges. Hospitals can make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms can be developed to identify errors before they become fatal. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240909880433/en/

Contacts

Patient Safety Movement Foundation

Patient Safety Movement Foundation
Irene Mulonni, irene@mulonni.com | (858) 859-7001

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release

-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization

Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release

Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou

Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release

Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi

Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release

Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin

Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release

Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye